• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Monthly September 2010

CenterWatch Monthly September 2010

September 1, 2010
CenterWatch Staff

"Sunshine law" puts cloud of concern over sponsors, sites

The sunshine law, part of the recent healthcare reform legislation, creates significant new obligations for drug sponsors by requiring that annual reports be submitted detailing their financial relationships with physicians and teaching hospitals. Both sponsors and investigative sites are trying to understand the scope of the law and have questioned whether it's possible to prevent a variety of unintended consequences that could harm clinical research and competitive confidentiality.

Academic Medical Centers and industry: Friends or foes?

Since drug development began, dysfunction and trouble have plagued the relationship between the commercial side of the industry -- sponsors and CROs -- and the academic side -- AMCs. Industry has long bemoaned that AMCs are too big, too slow, and too bureaucratic, while AMCs have complained that industry doesn't care about the patient or the science, but just wants to make money. Through the years, this tempestuous relationship has led the pendulum to swing both toward and away from collaboration, leading observers of the drug development process to question whether the two should work together at all. But as the industry matures and economic conditions remain tight, both sides are now striving to create better, more strategic partnerships.

Eye On: AstraZeneca

CenterWatch launches its new Eye On focusing on a single company's drug development pipeline this month with AstraZeneca, a worldwide biopharmaceutical company involved in discovery, development, manufacturing and marketing prescription drugs for six major therapeutic areas. Its strongest focus in terms of numbers of drugs in its pipeline includes oncology/inflammation, neuroscience and respiratory/inflammation. Other therapeutic areas include cardiovascular, gastrointestinal and infection. Research and development expenditures in 2008 exceeded $5 billion.

To read the full articles for this issue or for more information on these and other breaking stories, please click here for subscription information.

 

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing